Chikungunya Vaccines in Travel Medicine: From Regulatory Approval to Real-World Challenges
Tropical Medicine and Infectious Disease · 07.08.2026 · 11 (8) · 221
DOI: 10.3390/tropicalmed11080221 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Tropical Medicine and Infectious Disease, online erschienen am 07.08.2026. Verfasst von Yann Hervigo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Fribourg Hospital, 1752 Villars-sur-Glâne, Switzerland. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chikungunya virus (CHIKV) infection is an emerging disease of growing concern to international travelers due to the expanding geographic distribution of competent vectors, climate change, and frequent outbreaks in endemic and previously unaffected regions. Until recently, prevention relied exclusively on vector control and bite prevention; however, the recent approval of chikungunya vaccines has introduced a new preventive strategy.
Methods
We conducted a narrative review of currently licensed chikungunya vaccines and candidates in clinical development, focusing on immunogenicity, safety, regulatory status, and implications for travel medicine practice.
Results
Two vaccines have recently received regulatory approval: the live-attenuated vaccine IXCHIQ® and the virus-like particle vaccine Vimkunya®. Both demonstrated high immunogenicity based on neutralizing antibody thresholds accepted as surrogate markers of protection. Post-marketing safety signals associated with IXCHIQ®, particularly in older adults, have led to divergent regulatory decisions between authorities. The indication of vaccination in national recommendations varies somewhat depending on age, duration of travel, and individual risk factors. Several additional vaccine platforms remain under investigation, although some candidates have been discontinued.
Conclusions
The recent approval of chikungunya vaccines marks a significant milestone in the field of travel medicine. However, uncertainties regarding long-term protection, safety in specific populations, and optimal targeting of travelers remain. Individualized risk–benefit assessment is essential, and further data are needed to refine vaccination strategies for travelers and populations at risk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Internal Medicine, Fribourg Hospital, 1752 Villars-sur-Glâne, Switzerland.
- Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
- Swiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.
- University of Basel, 4001 Basel, Switzerland.
- Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.
- Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.
ORCID-Profile: Cornelia Staehelin, François Chappuis
Zitieren
APA
Hervigo, Y., Staehelin, C., Veit, O., Chappuis, F., Eperon, G., & Musumeci, S. (2026). Chikungunya Vaccines in Travel Medicine: From Regulatory Approval to Real-World Challenges. Tropical Medicine and Infectious Disease, 11(8), 221. https://doi.org/10.3390/tropicalmed11080221
Vancouver
Hervigo Y, Staehelin C, Veit O, Chappuis F, Eperon G, Musumeci S. Chikungunya Vaccines in Travel Medicine: From Regulatory Approval to Real-World Challenges. Tropical Medicine and Infectious Disease. 2026;11(8):221. doi:10.3390/tropicalmed11080221
BibTeX
@article{Hervigo2026,
author = {Hervigo, Yann and Staehelin, Cornelia and Veit, Olivia and Chappuis, François and Eperon, Gilles and Musumeci, Stefano},
title = {Chikungunya Vaccines in Travel Medicine: From Regulatory Approval to Real-World Challenges},
journal = {Tropical Medicine and Infectious Disease},
year = {2026},
volume = {11},
number = {8},
pages = {221},
doi = {10.3390/tropicalmed11080221}
}
EUVIMED